New understanding of B cell mutation strategies could have implications for vaccines
A vaccine's ability to generate long-lasting, high-affinity antibodies hinges on a delicate balance. Upon exposure to a ...
Healio11h
‘Landmark’ B-cell depletion data offer hope to patients with IgG4-related disease
Last November, results from the MITIGATE trial made headlines at ACR Convergence 2024 with positive phase 3 trial data for inebilizumab, an IgG1 monoclonal antibody targeting CD19, in patients with ...
Everyday Health7d
What Is Diffuse Large B-Cell Lymphoma (DLBCL)?
Explore diffuse large B-cell lymphoma — symptoms, causes, diagnosis, treatment options, and prevention. Learn about its types ...
Labroots1d
Immune Cell Mechanism Improves Antibody Production
Our immune system works to fight infections immediately, but also maintain long-term immunity. Two waves of protection help neutralize and eliminate diseas | Immunology ...
CURE4h
FDA Grants Fast Track Designation for Azer-Cel in Lymphoma Subset
FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...
Gene therapy for blood cancer shows 73 per cent response rate in clinical trials: Lancet study
A new study published in The Lancet Haematology journal says that an indigenously developed gene therapy for certain blood ...
Devdiscourse4d
Breakthrough Gene Therapy: A New Hope for Cancer Patients
An indigenously developed CAR T-cell gene therapy has achieved a 73% response rate for certain blood cancers in India. The ...
Study of CAR T-Cell therapy trial in India, in leukaemia patients, shows 73% response rate
India's gene therapy for blood cancers shows 73% response rate, offering hope and cost-effective treatment for patients.